Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price Expected to Rise, Truist Financial Analyst Says

02 May 2026, 08:43 by Jessica Moore · The Cerbat Gem

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) had its price objective increased by analysts at Truist Financial from $42.00 to $45.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Truist Financial’s target price would indicate a potential upside of 28.58% from the stock’s previous close.

Several other research analysts have also recently weighed in on the stock. Barclays increased their price target on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a report on Friday, January 30th. Jefferies Financial Group increased their price target on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th. The Goldman Sachs Group increased their price target on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday, February 9th. Finally, Piper Sandler reissued an “overweight” rating and issued a $41.00 price target (up from $40.00) on shares of Teva Pharmaceutical Industries in a report on Wednesday, March 4th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $41.56.

Get Our Latest Analysis on Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Trading Down 0.2%

Teva Pharmaceutical Industries stock opened at $35.00 on Thursday. Teva Pharmaceutical Industries has a 52 week low of $14.99 and a 52 week high of $37.35. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.80 and a current ratio of 1.01. The stock has a market capitalization of $40.24 billion, a P/E ratio of 26.31, a PEG ratio of 3.09 and a beta of 0.76. The stock has a 50-day simple moving average of $31.15 and a 200 day simple moving average of $29.33.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The business had revenue of $3.98 billion during the quarter. Analysts expect that Teva Pharmaceutical Industries will post 2.6 earnings per share for the current year.

Insider Transactions at Teva Pharmaceutical Industries

In other news, insider Placid Jover sold 14,150 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $448,130.50. Following the transaction, the insider directly owned 6,774 shares of the company’s stock, valued at approximately $214,532.58. This trade represents a 67.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Richard Daniell sold 17,295 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $547,732.65. Following the transaction, the executive vice president directly owned 85,755 shares in the company, valued at $2,715,860.85. This represents a 16.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 920,901 shares of company stock worth $30,056,789. 0.54% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in TEVA. Norges Bank bought a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth approximately $1,098,060,000. Harel Insurance Investments & Financial Services Ltd. increased its holdings in shares of Teva Pharmaceutical Industries by 19.2% during the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock worth $1,402,945,000 after purchasing an additional 7,255,083 shares during the period. Wellington Management Group LLP increased its holdings in shares of Teva Pharmaceutical Industries by 39,228.4% during the third quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock worth $139,296,000 after purchasing an additional 6,878,304 shares during the period. Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of Teva Pharmaceutical Industries by 18.8% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock worth $1,171,378,000 after purchasing an additional 5,917,423 shares during the period. Finally, Schroder Investment Management Group increased its holdings in shares of Teva Pharmaceutical Industries by 261.1% during the fourth quarter. Schroder Investment Management Group now owns 7,426,885 shares of the company’s stock worth $231,793,000 after purchasing an additional 5,370,253 shares during the period. 54.05% of the stock is owned by institutional investors.

Key Stories Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

Positive Sentiment: Q1 earnings beat and revenue upside driven by branded products (Austedo, Ajovy, Uzedy), which lifted investor sentiment and underpins near‑term earnings growth. Read More.
Positive Sentiment: Multiple broker upgrades and higher price targets — UBS, Truist, JPMorgan and Piper Sandler raised targets/ratings over the last day, signaling analyst confidence in a re‑rating and further upside for the stock. Read More. Read More.
Positive Sentiment: Teva agreed to acquire Emalex for ~\$900M to add ecopipam (paediatric Tourette’s) — a late‑stage, de‑risked asset that bolsters the specialty/innovative portfolio and supports the narrative that Teva is shifting toward higher‑margin branded growth. Read More.
Neutral Sentiment: Teva published its 2025 Healthy Future Report and says it met all sustainability‑linked bond targets — positive for ESG profile and potentially credit metrics, but unlikely to move near‑term revenues. Read More.
Neutral Sentiment: Blackstone put significant financing behind Teva in a recent deal — signals institutional interest/validation but primarily affects capital structure and optionality rather than immediate EPS. Read More.
Neutral Sentiment: Industry reports list Teva among leaders in oral solid dosage contract manufacturing — positive for long‑term service demand exposure but not an immediate earnings catalyst. Read More.
Negative Sentiment: Generics revenue remains weak even as branded sales grow — raises questions about sustainability of overall top‑line growth if branded momentum slows. Read More.
Negative Sentiment: After a rapid share run‑up, some analysts and coverage pieces note valuation/volatility risk — investors should weigh near‑term upside from upgrades against stretched multiples and execution risk. Read More.

Teva Pharmaceutical Industries Company Profile

(Get Free Report)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.